drug
spinosad
Marketedupdated 4mo agoby ParaPRO LLC
Approvedcommunity read0 votes
all catalysts(0)
nothing on the calendar yet
Trials studying spinosad
- phase2A Phase 2, Controlled, Double Blind, Randomized and Multicenter Study to Compare Efficacy and Safety of a Novel Topical Therapy (APT-001, Spinosad 1.8%) in Patients With Blepharitis.
- phase4PK and Safety Study of Natroba Topical Suspension 0.9% in Subjects 1 Month to 3 Years 11 Months of Age With Scabies
Patent cliff
source: FDA Orange Bookfirst barrier falls
Nov 25, 2033
~7.3 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (1)
- Nov 25, 2033method-of-use (U-3365)US 9895388
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 1h ago
Found something off?
comments(0)
5-min edit window · permanent after that